mebeverine has been researched along with Cytokine Release Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corrêa, CR; Costa, MR; de Mattei, L; de Paula, BH; Dos Santos, KC; Ferreira, ALA; Ferron, AJT; Francisqueti-Ferron, FV; Garcia, JL; Gregolin, CS; Lo, ÂTC; Minatel, IO; Moreto, F; Nakandakare-Maia, ET; Sarzi, F; Silva, CCVA; Silva, JPDC; Siqueira, JS | 1 |
1 other study(ies) available for mebeverine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: a hypothetical therapeutic for cytokine storm in COVID-19?
Topics: Adipose Tissue; Animals; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Inflammation; Male; Oxidative Stress; Phenylpropionates; PPAR gamma; Random Allocation; Rats; Rats, Wistar; SARS-CoV-2 | 2021 |